SCHEDULE 13G/A: Janus Henderson Group PLC Discloses 10.0% Passive Stake in Madrigal Pharmaceuticals, Inc.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 10.0% beneficial ownership stake in Madrigal Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• Janus Henderson Group PLC, a global asset manager, has reported beneficial ownership of 2,205,984 shares of Common Stock in Madrigal Pharmaceuticals, Inc.
• This ownership represents 10.0% of Madrigal Pharmaceuticals, Inc.'s outstanding Common Stock.
• The filing is an Amendment No. 5 to a Schedule 13G, indicating a change in their previously reported ownership.
• The securities are held with shared voting power and shared dispositive power, both amounting to 2,205,984 shares.
• Janus Henderson Group PLC certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It reflects a passive investment.

Positives

• The disclosure of a 10.0% stake by a major institutional investor like Janus Henderson Group PLC can signal confidence in Madrigal Pharmaceuticals, Inc.'s long-term prospects.
• Significant institutional ownership often provides a degree of stability to the stock's shareholder base.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding Madrigal Pharmaceuticals, Inc.'s business operations or financial performance. It solely pertains to beneficial ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Kristin Mariani, Head of North America Compliance, CCO for Janus Henderson Group PLC)

Industry Context

This filing indicates a significant passive investment by a large asset management firm, Janus Henderson Group PLC, in Madrigal Pharmaceuticals, Inc., a company operating in the pharmaceutical sector. Such institutional holdings are common in the biotechnology and pharmaceutical industries, where long-term investment in companies with promising drug pipelines is typical.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder can influence investor perception and potentially provide a sense of stability or validation for the company's stock.
• Company Management: Awareness of a large passive institutional holder may influence strategic decisions, though the filing explicitly states the investment is not for control purposes.

Key Dates

Keywords

Madrigal Pharmaceuticals, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology, Passive Investment